Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production

Virology

Volumn 267, Issue 2, 2000, Pages 237-246

  Blaak, Hetty ^a   Ran, Leonie J ^a   Rientsma, Ronald ^a   Schuitemaker, Hanneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ANTIGEN EXPRESSION; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NEUTROPHIL; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034652603     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.0111     Document Type: Article

References (48)

1. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
2. Alkhatib G., Locati M., Kennedy P. E., Murphy P. M., Berger E. A. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokine: Independence from G protein signaling and importance of coreceptor downmodulation. Virology. 234:1997;340-348.
3. - T-cell subset contains specialized primed cells. J. Immunol. 154:1995;17-25.
4. Balotta C., Bagnarelli P., Violi M., Ridolfo A. L., Zhou D., Berlusconi A., Corvasce S., Corbellino M., Clementi M., Clerici M., Moroni M., Galli M. Homozygous Δ32 deletion of the CCR5 chemokine receptor gene in an HIV-1 infected patient. AIDS. 11:1997;F67-F71.
5. Biti R., French R., Young J., Bennetts B., Stewart G., Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature Med. 3:1997;252-253.
6. Björndal Å., Deng H., Jansson M., Fiore J. R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D. R., Fenyö E. M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:1997;7478-7487.
7. Blaak H., Van 't Wout A. B., Brouwer M., Cornelissen M., Kootstra N. A., Albrecht-van Lent N., Keet R. P. M., Goudsmit J., Coutinho R. A., Schuitemaker H. Infectious cellular load in HIV-1-infected individuals and susceptibility of PBMC from their exposed partners to NSI HIV-1 as major determinants for HIV-1 transmission in homosexual couples. J. Virol. 72:1998;218-224.
8. Bleul C. C., Wu L., Hoxie J. A., Springer T. A., Mackay C. R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA. 94:1997;1925-1930.
9. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
10. Cocchi F., DeVico A. L., Garzino-Demo A., Arya S. K., Gallo R. C., Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1995;1811-1815.
11. Dean M., Carrington M., Winkler C., Huttley G. A., Smith M. W., Allikmets R., Goedert J. J., Buchbinder S. P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., Hemophilia Growth and Development Study Multicenter AIDS Cohort Study, O'Brien S. J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 273:1996;1856-1862.
12. Deng H. K., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Suttons R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. Identification of the major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
13. De Roda Husman A. M., Baak H., Brouwer M., Schuitemaker H. CCR5 cell-surface expression in relation to CCR5 genotype and the clinical course of HIV-1 infection. J. Immunol. 163:1999a;4597-4603.
14. De Roda Husman A. M., Koot M., Cornelissen M., Brouwer M., Broersen S. M., Bakker M., Roos M. Th. L., Prins M., De Wolf F., Coutinho R. A., Miedema F., Goudsmit J., Schuitemaker H. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 127:1997;882-890.
15. De Roda Husman A. M., van Rij R. P., Blaak H., Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for HIV-1 disease progression. J. Infect. Dis. 180:1999b;1106-1115.
16. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P., Paxton W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
17. Eugen-Olsen J., Iversen A. K. N., Garred P., Koppelhus U., Pedersen C., Benfield T. L., Sorensen A. M., Katzenstein T., Dickmeiss E., Gerstoft J., Skinhoj P., Svejgaard A., Nielsen J. O., Hofmann B. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:1997;305-310.
18. Furci L., Scarlatti G., Burastero S., Tambussi G., Colognesi C., Quillent C., Longhi R., Loverro P., Borgonovo B., Gaffi D., Carrow E., Malnati M., Lusso P., Siccardi A. G., Lazzarin A., Beretta A. Antigen-driven C-C-chemokine-mediated HIV-1 suppression by CD4+ T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J. Exp. Med. 186:1997;455-460.
19. + T cells. J. Exp. Med. 186:1997;1407-1418.
20. Huang Y., Paxton W. A., Wolinsky S. M., Neumann A. U., Zhang L., He T., Kang S., Ceradini D., Jin Z., Yazdanbakhsh K., Kunstman K., Erickson D., Dragon E., Landau N. R., Phair J., Ho D. D., Koup R. A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2:1996;1240-1243.
21. Kim A., Pettoello-Mantovani M., Goldstein H. Decreased susceptibility of peripheral blood mononuclear cells from individuals heterozygous for a mutant CCR5 allele to HIV-1 infection. J. Acquir. Immune. Defic. Syndr. Hum. R. 19:1998;145-149.
22. Kinter A. L., Ostrowski M., Goletti D., Oliva A., Weissman D., Gantt K., Hardy E., Jackson R., Ehler L., Fauci A. S. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous β-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. USA. 93:1996;14076-14081.
23. Koot M., Vos A. H. V., Keet R. P. M., De Goede R. E. Y., Dercksen W., Terpstra F. G., Coutinho R. A., Miedema F., Tersmette M. HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS. 6:1992;49-54.
24. Liu H., Chao D., Nakayama E. E., Taguchi H., Goto M., Xin X., Takamatsu J. K., Saito H., Ishikawa Y., Akaza T., Juji T., Takebe Y., Ohishi T., Fukutake K., Maruyama Y., Yashiki S., Sonoda S., Nakamura T., Nagai Y., Iwamoto A., Shioda T. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA. 96:1999;4581-4585.
25. Liu R., Paxton W. A., Choe S., Ceradini D., Martin S. R., Horuk R., MacDonald M. E., Stuhlmann H., Koup R. A., Landau N. R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:1996;1-20.
26. Margolis L. B., Glushakova S., Grivel J.-C., Murphy P. M. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. J. Clin. Invest. 101:1998;1876-1880.
27. Martin M. P., Dean M., Smith M. W., Winkler C., Gerrard B., Michael N. L., Lee B., Doms R. W., Margolick J., Buchbinder S., Goedert J. J., O'Brien T. R., Hilgartner M. W., Vlahov D., O'Brien S. J., Carrington M. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 282:1998;1907-1911.
28. McDermott D. H., Zimmerman P. A., Guignard F., Kleeberger C. A., Leitman S. F., Murphy P. M. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet. 352:1998;866-870.
29. Meyer L., Magierowska M., Hubert J.-B., Rouzioux C., Deveau C., Sanson F., Debre P., Delfraissy J.-F., Theodorou I. Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS. 11:1997;F73-F78.
30. Michael N. L., Chang G., Louie L. G., Mascola J. R., Dondero D., Birx D. L., Sheppard H. W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature Med. 3:1997;338-340.
31. Michael N. L., Nelson J. A. E., KewalRamani V. N., Chang G., O'Brien S. J., Mascola J. R., Volsky B., Louder M., White G. C. II, Littman D. R., Swanstrom R., O'Brien T. R. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J. Virol. 72:1998;6040-6047.
32. Morawetz R. A., Rizzardi G. P., Glauser D., Rutschmann O., Hirschel B., Perrin L., Opravil M., Flepp M., Von Overbeck J., Glauser M. P., Ghezzi S., Vicenzi E., Poli G., Lazzarin A., Pantaleo G. Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/ΔCCR5) genotype is neither essential nor sufficient for protection against disease progression. Eur. J. Immunol. 27:1997;3223-3227.
33. Mummidi S., Ahuja S. S., Gonzalez E., Anderson S. A., Santiago E. N., Stephan K. T., Craig F. E., O'Connell P., Tryon V., Clark R. A., Dolan M. J., Ahuja S. K. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med. 4:1998;786-793.
34. O'Brien T. R., Winkler C., Dean M., Nelson J. A., Carrington M., Michael N. L., White G. C. HIV-1 infection in a man homozygous for CCR5 Δ32. Lancet. 349:1997;1219.
35. Ostrowski M. A., Justement S. J., Cantanzaro A., Hallahan C. A., Ehler L. A., Mizell S. B., Kumar P. N., Mican J., Chun T.-W., Fauci A. S. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J. Immunol. 161:1998;3195-3201.
36. + lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemokines. Virology. 244:1998;66-73.
37. Paxton W. A., Martin S. R., Tse D., O'Brien T. R., Skurnick J., Vandevanter N. L., Padian N., Braun J. F., Kotler D. P., Wolinsky S. M., Koup R. A. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 2:1996;412-417.
38. Picchio G. R., Gulizia R. J., Mosier D. E. Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice. J. Virol. 71:1997;7124-7127.
39. Quillent C., Oberlin E., Braun J., Rousset D., Gonzalez-Canali G., Metais P., Montagnier L., Virelizier J.-L., Arenzana-Seisdedos F., Beretta A. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 351:1998;14-18.
40. Saha K., Bentsman G., Chess L., Volsky D. J. Endogenous production of β-chemokines by CD4+, but not CD8+ T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J. Virol. 72:1998;876-881.
41. Samson M., Libert F., Doranz B. J., Rucker J., Liesnard C., Farber C.-M., Saragosti S., Lapouméroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R. J., Collman R. G., Doms R. W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725.
42. Tersmette M., Winkel I. N., Groenink M., Gruters R. A., Spence P., Saman E., van der Groen G., Miedema F., Huisman J. G. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24gag. Virology. 171:1989;149-155.
43. Theodorou I., Meyer L., Magierowska M., Katlama C., Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 Δ32. Lancet. 346:1997;1219-1220.
44. Wu L., Paxton W. A., Kassam N., Ruffing N., Rottman J. B., Sullivan N., Choe H., Sodroski J., Newman W., Koup R. A., Mackay C. R. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185:1997;1681-1691.
45. Zagury D., Lachgar A., Chams V., Fall L. S., Bernard J., Zagury J. F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., O'Brien S. J., Burny A., Gallo R. C. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 95:1998;3857-3861.
46. Zhang L., He T., Huang Y., Chen Z., Guo Y., Wu S., Kunstman K. J., Brown R. C., Phair J. P., Neumann A. U., Ho D. D., Wolinsky S. M. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 72:1998;9307-9312.
47. Zhang Y.-J., Dragic T., Cao Y., Kostrikis L., Kwon D. S., Littman D. R., KewalRamani V. N., Moore J. P. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:1998;9337-9344.
48. Zimmerman P. A., Buckler-White A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C., Weissman D., Cohen O., Rubbert A., Lam G., Vaccarezza M., Kennedy P. E., Kumaraswami V., Giorgi J. V., Detels R., Hunter J., Chopek M., Berger E. A., Fauci A. S., Nutman T. B., Murphy P. M. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3:1997;23-36.